Catheter closure of atrial septal defect in patients with cryptogenic stroke: initial experience in Japan

详细信息    查看全文

• 作者：Yasufumi Kijima (1)
  Teiji Akagi (2)
  Manabu Taniguchi (2)
  Koji Nakagawa (1)
  Kentaro Deguchi (3)
  Tomoko Tomii (4)
  Kengo Kusano (1)
  Shunji Sano (4)
  Hiroshi Ito (1)
  
• 关键词：Atrial septal defect ; Patent foramen ovale ; Catheter closure ; Cryptogenic stroke
• 刊名：Cardiovascular Intervention and Therapeutics
• 出版年：2012
• 出版时间：January 2012
• 年：2012
• 卷：27
• 期：1
• 页码：8-13
• 全文大小：187KB
• 参考文献：1. Oho S, Ishizawa A, Akagi T, Dodo H, Kato H. Transcatheter closure of atrial septal defects with the Amplatzer septal occluder—a Japanese clinical trial. Circ J. 2002;66:791-. CrossRef
  2. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-0.
  3. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of risk in a community. Mayo Clin Proc. 1999;74:862-. CrossRef
  4. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, et al. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11-. CrossRef
  5. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148-2. CrossRef
  6. Hausmann D, Mügge A, Becht I, Daniel WG. Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. Am J Cardiol. 1992;70:668-2. CrossRef
  7. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740-. CrossRef
  8. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55:1172-.
  9. Bannan A, Shen R, Silvestry FE, Herrmann HC. Characteristics of adult patients with atrial septal defects presenting with paradoxical embolism. Catheter Cardiovasc Interv. 2009;74:1066-. CrossRef
  10. Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus J, Reisman M, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005;46:1768-6. CrossRef
  11. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409-9.
  12. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461-.
  13. Ueno Y, Iguchi Y, Inoue T, Shibazaki K, Urabe T, Kimura K. Paradoxical brain embolism may not be uncommon-prospective study in acute ischemic stroke. J Neurol. 2007;254:763-. CrossRef
  14. Khositseth A, Cabalka AK, Sweeney JP, Fortuin FD, Reeder GS, Connolly HM, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc. 2004;79:35-1. CrossRef
  15. Schwerzmann M, Windecker S, Wahl A, Mehta H, Nedeltchev K, Mattle H, et al. Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy. Heart. 2004;90:186-0. CrossRef
  16. Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J. 2004;25:424-0. CrossRef
  17. Diaz T, Cubeddu RJ, Rengifo-Moreno PA, Cruz-Gonzalez I, Solis-Martin J, Buonanno FS, et al. Management of residual shunts after initial percutaneous patent foramen ovale closure: a single center experience with immediate and long-term follow-up. Catheter Cardiovasc Interv. 2010;76:145-0. CrossRef
  18. Kizer JR, Devereux RB. Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med. 2005;353:2361-2. CrossRef
  19. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262-. CrossRef
  20. O’Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation. 2009;119:2743-. CrossRef
  21. O’Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2009;53:2014-. CrossRef
  22. Dalen JE. Are patients with a patent foramen ovale at increased risk of stroke? A billion dollar question. Am J Med. 2007;120:472-. CrossRef
  23. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-1. CrossRef
  24. Kent DM, Thaler DE. Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke. 2010;41:S26-0. CrossRef
  25. Bruch L, Parsi A, Grad MO, Rux S, Burmeister T, Krebs H, et al. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: single-center experience. Circulation. 2002;105:2845-. CrossRef
  26. Braun MU, Fassbender D, Schoen SP, Haass M, Schraeder R, Scholtz W, et al. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol. 2002;39:2019-5. CrossRef
  27. Khairy P, O’Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139:753-0.
  28. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750-. CrossRef
  29. Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101:77-2. CrossRef
  30. Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv. 2006;68:741-. CrossRef
  
• 作者单位：Yasufumi Kijima (1)
  Teiji Akagi (2)
  Manabu Taniguchi (2)
  Koji Nakagawa (1)
  Kentaro Deguchi (3)
  Tomoko Tomii (4)
  Kengo Kusano (1)
  Shunji Sano (4)
  Hiroshi Ito (1)
  
  1. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  2. Cardiac Intensive Care Unit, Okayama University Hospital, 2-5-1 Shicata-cho, Kitaku, Okayama, 7008558, Japan
  3. Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  4. Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  

文摘

A recent study has shown that cryptogenic stroke can occur even in patients with small or insignificant atrial septal defects (ASD). However, clinical experience in this field is still limited in Japan, also the efficacy and safety of catheter closure of such defects have not been identified. To evaluate the efficacy and safety of catheter closure of interatrial communication in patients with cryptogenic stroke, 13 patients who were diagnosed with cerebrovascular events due to cryptogenic embolism were included in this study. Mean age at procedure was 43?±?15 (range 17-8) years. In all patients, the presence of spontaneous or provoked interatrial right-to-left shunts was demonstrated by transesophageal contrast echocardiography. Mean defect size evaluated by the balloon sizing technique was 9.2?±?2.8?mm, and mean size of the Amplatzer Septal Occluder deployed was 9.5?±?2.8?mm. Devices were successfully deployed in all patients, though one device migrated into the descending aorta was retrieved by a snare catheter. Complete closure was detected by transesophageal contrast echocardiography at 12?months after the procedure was in 11 (85%) of the 13 patients. During the follow-up period (30.1?±?9.4?months), no recurrent thromboembolic event was observed. Catheter closure of interatrial right-to-left communications can be safely performed. This procedure may contribute to reduction or prevention of recurrent neurological events in this patient population.